主 頁 > 新 聞 及 資 訊

新 聞 及 資 訊   Important safety information on use of Zyprexa (olanzapine) in adolescents (English only)   Lilly and US Food and Drug Administration (FDA) notified healthcare professionals of recent extension of approval of Zyprexa to use in adolescents (ages 13-17) for treatment of schizophrenia and bipolar I disorder [manic or mixed episodes], but that in deciding its use for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents. Please refer to the website of US FDA for details: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198402.htm In Hong Kong, Zyprexa is registered by Eli Lilly Asia Inc (HK Branch), and it is not recommended for use in children and adolescents under 18 years of age. Ends/Tuesday, February 2, 2010 Issued at HKT 12:00